BNKL — Bionik Laboratories Share Price
Last trade - 00:00- $0.00m
- $1.73m
- $1.81m
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | n/a | ||
| Price to Tang. Book | n/a | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | 0 | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -458.22% | ||
| Return on Equity | -768.84% | ||
| Operating Margin | -267.29% | ||
Financial Summary
| Year End 31st Mar | Unit | 2019 | 2020 | 2021 | 2022 | 2023 | 2024E | 2025E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | 3.25 | 2.15 | 1.19 | 1.27 | 1.81 | n/a | n/a | 12.82% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Bionik Laboratories Corp. is a healthcare company focused on supplying solutions to those with movement impairments. Its product portfolio includes three InMotion Robots for rehabilitation following stroke and other neurological conditions and four products in varying stages of development. The InMotion robots offer patient-adaptive therapy, intended to restore upper-extremity motor control for a range of neurological conditions and recovery stages, including early recovery from acute stroke. InMotion Robots also provide objective evaluation assessments intended to measure and report the patient’s level of motor impairment and progress during therapy. Its solutions include InMotion Therapy, InMotion ARM, InMotion ARM/HAND, InMotion EVAL, InMotion Connect, InMotion for Physical Therapy, and InMotion for Occupational Therapy. InMotion Robotics provides the occupational therapist with a range of useful protocols designed to reduce many types of upper extremity neurological impairments.
Directors
- Andre-Jacques Auberton-Herve CHM (59)
- Richard Russo CEO (41)
- Loren Wass OTH (59)
- Remi Gaston-Dreyfus IND (65)
- Peter Malone IND (71)
- Joseph Martin IND (74)
- Charles Matine IND (62)
- Michal Prywata IND (29)
- Audrey Thevenon IND (43)
- Last Annual
- March 31st, 2023
- Last Interim
- March 31st, 2023
- Incorporated
- June 25th, 2013
- Public Since
- June 12th, 2012
- No. of Shareholders
- 315
- No. of Employees
- 12
- Sector
- Healthcare Equipment & Supplies
- Industry
- Healthcare
- Exchange
- Pink Sheets on Nasdaq
- Shares in Issue
- 12,480,431
- Address
- 80 Coolidge Hill Road, WATERTOWN, 02472
- Web
- https://www.bioniklabs.com/
- Phone
- +1 6179264800
- Contact
- Richard Russo
- Auditors
- MNP LLP
Upcoming Events for BNKL
Similar to BNKL
Aamaxan Transport
Pink Sheets on Nasdaq
ACCUSTEM SCIENCES
Pink Sheets on Nasdaq
Acutus Medical
Pink Sheets on Nasdaq
ADM Tronics Unlimited
Pink Sheets on Nasdaq
Advanced Biomedical Technologies
Pink Sheets on Nasdaq
FAQ
As of Today at 19:36 UTC, shares in Bionik Laboratories are trading at $0.00. This share price information is delayed by 15 minutes.
Shares in Bionik Laboratories last closed at $0.00 and the price had moved by +9900% over the past 365 days. In terms of relative price strength the Bionik Laboratories share price has outperformed the S&P500 Index by +9242.66% over the past year.
There is no consensus recommendation for this security.
Find out moreBionik Laboratories does not currently pay a dividend.
Bionik Laboratories does not currently pay a dividend.
Bionik Laboratories does not currently pay a dividend.
To buy shares in Bionik Laboratories you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
As of the previous close price of $0.00, shares in Bionik Laboratories had a market capitalisation of $0.00m.
Here are the trading details for Bionik Laboratories:
- Country of listing: United States
- Exchange: PNK
- Ticker Symbol: BNKL
Based on an overall assessment of its quality, value and momentum Bionik Laboratories is currently classified as a . The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
We could not find analyst target price data for this security.
Find out moreAn important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Bionik Laboratories. Over the past six months, its share price has outperformed the S&P500 Index by +10251.48%.
As of the last closing price of $0.00, shares in Bionik Laboratories were trading matched their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
The Bionik Laboratories PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at $0.00.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Bionik Laboratories' management team is headed by:
- Andre-Jacques Auberton-Herve - CHM
- Richard Russo - CEO
- Loren Wass - OTH
- Remi Gaston-Dreyfus - IND
- Peter Malone - IND
- Joseph Martin - IND
- Charles Matine - IND
- Michal Prywata - IND
- Audrey Thevenon - IND